![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H21NO3 |
Molar mass | 275.348 g·mol−1 |
3D model (JSmol) | |
| |
|
Acetoxymethylketobemidone (O-AMKD), is an opioid designer drug related to ketobemidone, with around the same potency as morphine. It was first identified in Germany in October 2020.[1][2]
See also
[edit]- 2F-Viminol
- 3-HO-PCP
- 4-Fluoropethidine
- Acetoxyketobemidone
- Bucinnazine
- Dipyanone
- Etodesnitazene
- Methylketobemidone
- Nortilidine
- O-Desmethyltramadol
- Piperidylthiambutene
- Propylketobemidone
References
[edit]- ^ European Monitoring Center for Drugs and Drug Addiction (December 2020). "New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic" (PDF). An Update from the EU Early Warning System. Luxembourg: Publications Office of the European Union. doi:10.2810/921262. ISBN 9789294975584.
- ^ Lamy FR, Daniulaityte R, Barratt MJ, Lokala U, Sheth A, Carlson RG (August 2021). ""Etazene, safer than heroin and fentanyl": Non-fentanyl novel synthetic opioid listings on one darknet market". Drug and Alcohol Dependence. 225: 108790. doi:10.1016/j.drugalcdep.2021.108790. PMID 34091156. S2CID 235362241.